Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NK510 +/- mAbs in advanced gastric cancer
NCT06098898Phase 1Enrolling by invitation
- Sponsor
- Base Therapeutics
- Start
- Nov 2023
- Primary completion
- Nov 2024
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label trial of NK510 in gastric cancer (GC) (3 arms), sponsored by Base Therapeutics. Primary endpoints: Dose-Limiting Toxicity at 6 weeks and Maximal Tolerable Dose at 6 weeks. Started Nov 2023; status: enrolling by invitation.
02
Drugs
NK510
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT06098898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06098898.